• Metronidazole: Advanced OAT3 Modulation for Microbiome Resea

  2026-06-25

  Explore the dual role of Metronidazole in OAT3 inhibition and microbiome modulation. This in-depth analysis uncovers new dimensions for research on drug-drug interactions and immune-microbiota dynamics.

• MK-0812 and TM6SF2: Advancing Monocyte Trafficking Inhibitio

  2026-06-25

  MK-0812, a potent CCR2 antagonist, is redefining translational strategies for metabolic dysfunction-associated steatohepatitis (MASH) through precision monocyte trafficking inhibition. Integrating recent mechanistic insights on the intestinal TM6SF2–gut–liver axis, this thought-leadership piece guides researchers in designing robust models and interventions for MASH and highlights the role of MK-0812 as an indispensable tool for immunometabolic research.

• (-)-Arctigenin as a MEK1 Inhibitor: Precision Cancer Workflo

  2026-06-24

  Harness the unique dual-action of (-)-Arctigenin as a MEK1 inhibitor and iNOS expression modulator to dissect macrophage-driven NF-κB signaling in breast cancer research. This guide delivers stepwise protocols, advanced troubleshooting, and translational insights for maximizing reproducibility and mechanistic clarity.

• Tivozanib (AV-951) in Oncology: Protocols, Optimization, and

  2026-06-23

  Tivozanib (AV-951) delivers exceptional selectivity and potency for dissecting VEGFR signaling and anti-angiogenic therapy in preclinical cancer models. This article provides actionable protocols, troubleshooting strategies, and key innovations that distinguish Tivozanib in advanced oncology research.

• 1-methyl Adenosine: Translational Leverage in RNA Modificati

  2026-06-23

  This thought-leadership article explores how 1-methyl Adenosine advances mechanistic and translational research in RNA modification, cancer metabolism studies, and biomarker discovery. Integrating the latest quantification methods with mechanistic insights, it offers strategic guidance for researchers navigating the path from bench to clinic, while highlighting APExBIO's offering and expanding on recent analytical and biological breakthroughs.

• AR and ARv7 in TNBC: Prognostic Impact and Enzalutamide Modu

  2026-06-22

  This study investigates androgen receptor (AR) and its splice variant ARv7 as prognostic markers in triple-negative breast cancer (TNBC), revealing their association with poor clinical outcomes and increased metastasis. Targeting AR/ARv7 with Enzalutamide significantly modulates metastatic and EMT markers in vitro, highlighting a translational bridge from prostate to breast cancer research.

• Anlotinib Hydrochloride: Advanced Workflows for Angiogenesis

  2026-06-22

  Anlotinib hydrochloride stands out as a potent multi-target tyrosine kinase inhibitor, enabling precise dissection of angiogenesis and tumor biology in advanced cancer research models. This guide delivers stepwise protocols, workflow enhancements, and troubleshooting strategies to maximize reproducibility and performance in endothelial migration and tube formation assays.

• Melatonin Attenuates Atrazine-Induced Renal Necroptosis via

  2026-06-21

  This study uncovers how melatonin mitigates atrazine-induced kidney injury by inhibiting RIPK3-dependent necroptosis. The findings highlight a mechanistic basis for melatonin's renal protection and suggest new strategies for addressing chemical-induced nephrotoxicity.

• Bedaquiline: Diarylquinoline Antibiotic for TB & Cancer Work

  2026-06-20

  Bedaquiline stands out as a dual-action diarylquinoline antibiotic, offering robust solutions for both multi-drug resistant tuberculosis treatment and cancer stem cell inhibition. Explore how APExBIO’s Bedaquiline enables advanced experimental designs, precise energy metabolism targeting, and workflow resilience in complex cellular models.

• NF 340: A Selective P2Y11 Antagonist for GPCR Research

  2026-06-19

  NF 340 is a high-selectivity P2Y11 antagonist with proven utility in modulating GPCR signaling. It is used to dissect inflammation and cancer cell invasion pathways. As a research-only reagent, NF 340 enables mechanistic studies without diagnostic or therapeutic application.

• Annexin V-PE Reagent: Precision Apoptosis Detection Workflow

  2026-06-19

  The Annexin V-PE Reagent streamlines early apoptosis detection with a rapid, one-step protocol adaptable to both flow cytometry and microscopy. By bridging recent structural insights from CD38 CAR-T research with robust assay design, this guide empowers researchers to maximize reliability, sensitivity, and throughput in apoptotic cell detection.

• Harnessing MK-0812: Advancing Monocyte Trafficking Inhibitio

  2026-06-18

  This article offers a strategic, evidence-driven perspective on leveraging MK-0812, a potent CCR2 antagonist, to dissect and inhibit monocyte trafficking in metabolic dysfunction-associated steatohepatitis (MASH). By integrating mechanistic insights from recent gut–liver axis research and TM6SF2 biology, we provide translational researchers with guidance for experimental design, protocol optimization, and future directions that extend beyond standard product documentation.

• Applied Cyanidin Chloride for Oxidative Stress and Skin Mode

  2026-06-18

  Cyanidin Chloride, a potent anthocyanin polyphenolic antioxidant from Bilberry, enables robust oxidative stress and inflammatory skin disease research with proven cell protectant and barrier-restorative effects. This guide translates recent reference breakthroughs and practical workflows into actionable protocols and troubleshooting strategies for advanced cell-based assays.

• Metronidazole as a Strategic Modulator of Drug Uptake Pathwa

  2026-06-17

  Explore Metronidazole’s dual role as an antibiotic and a selective OAT3 inhibitor, highlighting its impact on drug-drug interactions and experimental assay design. This article uniquely dissects transporter biology and assay optimization, setting it apart from existing resources.

• Lopinavir Identified as a MERS-CoV Inhibitor in Drug Repurpo

  2026-06-17

  de Wilde et al. performed a systematic screen of FDA-approved drugs and identified Lopinavir (ABT-378) as one of four small molecules that inhibit MERS-CoV replication in cell culture. This finding highlights the translational potential of repurposing HIV protease inhibitors for emerging coronavirus threats and provides a framework for rapid antiviral research.

15032 records 1/1003 page Next 12345 下5页 Last page